https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Biomarkers and anastomotic leakage in colorectal surgery: C-reactive protein trajectory is the gold standard https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36033 Wed 29 Jan 2020 11:59:09 AEDT ]]> Post-discharge opioid prescribing after laparoscopic appendicectomy and cholecystectomy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41981 Wed 24 May 2023 14:23:09 AEST ]]> C1q and mobility score in predicting sarcopenia in an Australian cohort of cancer surgery patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52162 Wed 04 Oct 2023 10:50:47 AEDT ]]> A Pilot Study: Intraoperative 16S rRNA Sequencing Versus Culture in Predicting Colorectal Incisional Surgical Site Infection https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52909 Wed 01 Nov 2023 08:47:04 AEDT ]]> Patient perceptions of surgical telehealth consultations during the COVID 19 pandemic in Australia: Lessons for future implementation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50019 Tue 27 Jun 2023 14:48:47 AEST ]]> High-dose preoperative cholecalciferol to prevent post-thyroidectomy hypocalcaemia: A randomized, double-blinded placebo-controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36646 Tue 23 Jun 2020 09:22:45 AEST ]]> Venous thromboembolic prophylaxis: current practice of surgeons in Australia and New Zealand for major abdominal surgery https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53495 90% use all three forms of VTE prophylaxis at some stage of treatment. Most surgeons do not vary practice between laparoscopic and open colectomy/major abdominal surgery and only 33% prescribe post-discharge chemical prophylaxis. 42% of surgeons surveyed had equipoise for a clinical trial on the use of IPCDs and the vast majority (> 95%) feel that IPCDs should provide at least a 2% improvement in VTE event rate in order to justify their routine use. Conclusion: Most surgeons in Australia and New Zealand do not use risk assessment tools and use all three forms of prophylaxis regardless. Therfore there is a gap between practice and VTE prophylaxis for the use of mechanical prophylaxis options. Further research is required to determine whether dual modality mechanical prophylaxis is incrementally efficacious. Trial Registration- Not Applicable.]]> Thu 30 Nov 2023 15:43:30 AEDT ]]> Antiseptic Skin Agents to Prevent Surgical Site Infection after Incisional Surgery: A Randomized, Three-armed Combined Non-inferiority and Superiority Clinical Trial (NEWSkin Prep Study) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46513 Thu 24 Nov 2022 15:43:28 AEDT ]]> Mobility scores as a predictor of length of stay in general surgery: a prospective cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43282 Thu 15 Sep 2022 12:23:29 AEST ]]> The effect of preoperative skin preparation on clinical outcomes with incisional surgery: a network meta-analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52228 Thu 05 Oct 2023 10:31:13 AEDT ]]> Transversus abdominis plane blockade in laparoscopic colorectal surgery: a double-blind randomized clinical trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27788 Sat 24 Mar 2018 07:23:23 AEDT ]]> Antiseptic Skin Agents to Prevent Surgical Site Infection After Clean Implant Surgery: Subgroup Analysis of the NEWSkin Prep Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54018 Mon 29 Jan 2024 13:26:25 AEDT ]]> Antiseptic Skin Preparation Agents to Prevent Surgical Site Infection in Colorectal Surgery: A 3-Armed Randomized Controlled Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48940 Mon 17 Apr 2023 14:57:53 AEST ]]> Utilization of telehealth by surgeons during the COVID 19 pandemic in Australia: lessons learnt https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49433 Mon 15 May 2023 13:44:13 AEST ]]> Long-Term Health-Related Quality of Life Outcomes Following Thyroid Surgery for Malignant or Benign Disease: Deficits Persist in Cancer Survivors Beyond Five Years https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50755 Mon 07 Aug 2023 15:25:43 AEST ]]> Randomized clinical trial to assess the ideal mode of delivery for local anaesthetic abdominal wall blocks https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41269 Mon 01 Aug 2022 09:49:35 AEST ]]> Tranexamic Acid for Lower GI Hemorrhage: A Randomized Placebo-Controlled Clinical Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41856 18 years with lower GI hemorrhage requiring hospital admission from November 2011 to January 2014 were screened for trial eligibility (N = 265). INTERVENTIONS: A total of 100 patients were recruited after exclusions and were randomly assigned 1:1 to either tranexamic acid or placebo. MAIN OUTCOME MEASURES: The primary outcome was blood loss as determined by reduction in hemoglobin levels. The secondary outcomes were transfusion rates, transfusion volume, intervention rates for bleeding, length of hospital stay, readmission, and complication rates. RESULTS: There was no difference between groups with respect to hemoglobin drop (11 g/L of tranexamic acid vs 13 g/L of placebo; p = 0.9445). There was no difference with respect to transfusion rates (14/49 tranexamic acid vs 16/47 placebo; p = 0.661), mean transfusion volume (1.27 vs 1.93 units; p = 0.355), intervention rates (7/49 vs 13/47; p = 0.134), length of hospital stay (4.67 vs 4.74 d; p = 0.934), readmission, or complication rates. No complications occurred as a direct result of tranexamic acid use. LIMITATIONS: A larger multicenter trial may be required to determine whether there are more subtle advantages with tranexamic acid use in some of the secondary outcomes. CONCLUSIONS: Tranexamic acid does not appear to decrease blood loss or improve clinical outcomes in patients presenting with lower GI hemorrhage in the context of this trial. see Video Abstract at https://links.lww.com/DCR/A453.]]> Fri 12 Aug 2022 17:04:19 AEST ]]>